Last reviewed · How we verify
Malathion lotion 0.5%
At a glance
| Generic name | Malathion lotion 0.5% |
|---|---|
| Also known as | OVIDE lotion |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice (PHASE3)
- Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice (PHASE1)
- Ivermectin in the Treatment of Head Lice (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Malathion lotion 0.5% CI brief — competitive landscape report
- Malathion lotion 0.5% updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI